The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
- PMID: 1967191
- DOI: 10.1056/NEJM199001183220305
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
Abstract
We evaluated three cellular and five serologic markers that are affected by infection with the human immunodeficiency virus type 1 (HIV-1) for their ability to predict the progression to clinical acquired immunodeficiency syndrome (AIDS). The cellular markers were the number of CD4+ T cells, the number of CD8+ T cells, and the ratio of CD4+ T cells to CD8+ T cells. The serologic markers were the serum levels of neopterin (a product of stimulated macrophages), beta 2-microglobulin, soluble interleukin-2 receptors, IgA, and HIV p24 antigen. We evaluated the usefulness of these measures as markers of the progression to AIDS prospectively, over four years, in a cohort of 395 HIV-seropositive homosexual men who were initially free of AIDS. CD4+ T cells (expressed as an absolute number, a percentage of lymphocytes, or a ratio of CD4+ to CD8+ T cells) were the best single predictor of the progression to AIDS, but the serum neopterin and beta 2-microglobulin levels each had nearly as much predictive power. The neopterin level appeared to be a slightly better predictor than the beta 2-microglobulin level. The levels of IgA, interleukin-2 receptors, and p24 antigen had less predictive value. A stepwise multivariate analysis indicated that the best predictors, in descending order, were CD4+ T cells (the percentage of lymphocytes or the CD4+: CD8+ ratio), the serum level of neopterin or beta 2-microglobulin, the level of IgA, that of interleukin-2 receptors, and that of p24 antigen. The last three markers had little additional predictive power beyond that of the first two. We conclude that of the eight markers studied, progression to AIDS was predicted most accurately by the level of CD4+ T cells in combination with the serum level of either neopterin or beta 2-microglobulin. At least one of these two serum markers, which reflect immune activation, should be used along with measurement of CD4+ T cells in disease-classification schemes and in the evaluation of responses to therapy.
Comment in
-
Markers of risk in HIV-1.N Engl J Med. 1990 Jun 28;322(26):1886. doi: 10.1056/NEJM199006283222612. N Engl J Med. 1990. PMID: 1971915 No abstract available.
Similar articles
-
Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection.Infection. 1991;19 Suppl 2:S98-102. doi: 10.1007/BF01644476. Infection. 1991. PMID: 1673120 Review.
-
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.Dis Markers. 1990 May-Jun;8(3):164-5. Dis Markers. 1990. PMID: 2125538 No abstract available.
-
[Lymphocyte subpopulations, neopterin, and beta-2-microglobulin: relationship with clinical stage, risk of progression to AIDS and presence of active infection in HIV infection].Enferm Infecc Microbiol Clin. 1993 Aug-Sep;11(7):373-7. Enferm Infecc Microbiol Clin. 1993. PMID: 8104488 Spanish.
-
HLA class I soluble antigen serum levels in HIV-positive subjects--correlation with cellular and serological parameters.Cancer Detect Prev. 1990;14(3):321-3. Cancer Detect Prev. 1990. PMID: 2117484
-
Neopterin and human immunodeficiency virus infection.Eur J Clin Chem Clin Biochem. 1993 Apr;31(4):191-5. doi: 10.1515/cclm.1993.31.4.191. Eur J Clin Chem Clin Biochem. 1993. PMID: 8100453 Review.
Cited by
-
Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.Clin Exp Immunol. 1992 Jun;88(3):548-54. doi: 10.1111/j.1365-2249.1992.tb06485.x. Clin Exp Immunol. 1992. PMID: 1606739 Free PMC article.
-
Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection.Infection. 1991;19 Suppl 2:S98-102. doi: 10.1007/BF01644476. Infection. 1991. PMID: 1673120 Review.
-
Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.PLoS One. 2010 Feb 22;5(2):e9138. doi: 10.1371/journal.pone.0009138. PLoS One. 2010. PMID: 20179751 Free PMC article. Clinical Trial.
-
Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.Am J Hum Genet. 2010 Jan;86(1):88-92. doi: 10.1016/j.ajhg.2009.12.008. Epub 2009 Dec 31. Am J Hum Genet. 2010. PMID: 20045101 Free PMC article.
-
MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands.J Virol. 2007 Aug;81(15):8180-91. doi: 10.1128/JVI.00421-07. Epub 2007 May 16. J Virol. 2007. PMID: 17507480 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous